{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:26:34Z","timestamp":1794590794687,"version":"4.9.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"DOI":"10.1182\/bloodadvances.2026021426","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:03:30Z","timestamp":1790370210000},"page":"7767-7770","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Discontinuation of targeted therapy in histiocytic neoplasms with durable responses: the DOTT-HN study"],"prefix":"10.1182","volume":"10","author":[{"given":"Xi","family":"Yang","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haadi","family":"Ali","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bossert","sequence":"additional","affiliation":[{"name":"2Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla I.","family":"Borre","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinda H.","family":"Shukla","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn E. F.","family":"Speer","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corbin","family":"Wright","sequence":"additional","affiliation":[{"name":"5Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-3443","authenticated-orcid":false,"given":"Fnu","family":"Amisha","sequence":"additional","affiliation":[{"name":"5Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Reynolds","sequence":"additional","affiliation":[{"name":"5Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-6252","authenticated-orcid":false,"given":"Jithma","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-5961","authenticated-orcid":false,"given":"Eli","family":"Diamond","sequence":"additional","affiliation":[{"name":"2Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asra","family":"Ahmed","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2026111311221573600_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"2026111311221573600_bib2","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.mayocp.2019.02.023","article-title":"The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease","volume":"94","author":"Goyal","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2026111311221573600_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","article-title":"Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation","volume":"124","author":"Hervier","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2026111311221573600_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2026111311221573600_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600\u2013mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7749","key":"2026111311221573600_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"2026111311221573600_bib7","doi-asserted-by":"crossref","first-page":"1070828","DOI":"10.3389\/fmed.2022.1070828","article-title":"Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease","volume":"9","author":"Cronin","year":"2022","journal-title":"Front Med"},{"key":"2026111311221573600_bib8","doi-asserted-by":"crossref","first-page":"1305518","DOI":"10.3389\/fonc.2024.1305518","article-title":"Case report: targeted treatment strategies for Erdheim-Chester disease","volume":"14","author":"Guly\u00e1s","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"2026111311221573600_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"15","key":"2026111311221573600_bib10","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis","volume":"7","author":"Aaroe","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2026111311221573600_bib11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026111311221573600_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.18964","article-title":"Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms","volume":"203","author":"Reiner","year":"2023","journal-title":"Br J Haematol"},{"issue":"25","key":"2026111311221573600_bib13","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026111311221573600_bib14","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41375-025-02656-w","article-title":"Cluster analysis reveals the clinical spectrum of Erdheim-Chester disease: myelodysplastic neoplasm","volume":"39","author":"Tesi","year":"2025","journal-title":"Leukemia"},{"issue":"20","key":"2026111311221573600_bib15","doi-asserted-by":"crossref","first-page":"e2746","DOI":"10.1212\/WNL.0000000000010748","article-title":"Central nervous system involvement in Erdheim-Chester disease: an observational cohort study","volume":"95","author":"Cohen Aubart","year":"2020","journal-title":"Neurology"},{"issue":"10295","key":"2026111311221573600_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","article-title":"Histiocytosis","volume":"398","author":"Emile","year":"2021","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7767\/2600554\/blooda_adv-2026-021426-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7767\/2600554\/blooda_adv-2026-021426-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:22:24Z","timestamp":1794586944000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7767\/571236\/Discontinuation-of-targeted-therapy-in-histiocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":16,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021426","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}